Wipe sampling procedure coupled to LC–MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces
- 787 Downloads
A simple wipe sampling procedure was developed for the surface contamination determination of ten cytotoxic drugs: cytarabine, gemcitabine, methotrexate, etoposide phosphate, cyclophosphamide, ifosfamide, irinotecan, doxorubicin, epirubicin and vincristine. Wiping was performed using Whatman filter paper on different surfaces such as stainless steel, polypropylene, polystyrol, glass, latex gloves, computer mouse and coated paperboard. Wiping and desorption procedures were investigated: The same solution containing 20% acetonitrile and 0.1% formic acid in water gave the best results. After ultrasonic desorption and then centrifugation, samples were analysed by a validated liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS) in selected reaction monitoring mode. The whole analytical strategy from wipe sampling to LC–MS/MS analysis was evaluated to determine quantitative performance. The lowest limit of quantification of 10 ng per wiping sample (i.e. 0.1 ng cm−2) was determined for the ten investigated cytotoxic drugs. Relative standard deviation for intermediate precision was always inferior to 20%. As recovery was dependent on the tested surface for each drug, a correction factor was determined and applied for real samples. The method was then successfully applied at the cytotoxic production unit of the Geneva University Hospitals pharmacy.
KeywordsCytotoxic Antineoplastic drugs Surface contamination Environmental monitoring LC–MS/MS Wipe sampling
The authors kindly thank the Proteomics Core Facility at the Faculty of Medicine, University of Geneva (Switzerland) for the loan of the LC-MS/MS instrument and the Unit of Toxicology, University Center of Legal Medicine, Geneva (Switzerland) for the wiping papers.
- 3.BGW (2009) Forschungsprojekt MEWIP. http://www.pharma-monitor.de/download_mewip/MEWIP-Abschlussbericht_Sept_2008.pdf. Accessed 20 July 2010
- 4.Latour JF (2008) Eur J Hosp Pharm Pract—ESMO Supplement, pp 23–25Google Scholar
- 5.Weir PJ, Rigge DC, Holmes A, Fox E (2009) Hosp Pharm Eur 47:58–60Google Scholar
- 8.Connor TH, Anderson RW, Sissink PJM, Broadfiled L, Power L (1999) Am J Health Syst Pharm 56:1427–1432Google Scholar
- 12.Schreiber C, Radon K, Pethran A, Schierl R, Hauff K, Grimm C-H, Boos K-S, Nowak D (2003) Int Arch Occup Environ Health 76:11–16Google Scholar
- 13.Pethran A, Schierl R, Hauff K, Grimm C-H, Boos K-S, Nowak D (2003) Int Arch Occup Environ Health 76:5–10Google Scholar
- 21.Schmaus G, Schierl R, Funck S (2002) Am J Health Syst Pharm 59:956–961Google Scholar